Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Therapeutic Manipulation of Glioblastoma Microenvironments using Tumor-derived Exosomes

FY 2010-11

Summary
Glioma is the most prominent type of CNS tumour and accounts for more than 65% of all primary brain tumors. Between Canada and the United States, more than 100,000 patients are diagnosed with a brain tumor annually, representing a major health burden on the individual as well as society. Furthermore, therapeutic strategies often pose a high risk of side effects to glioma patients due to its occurrence in the brain, and invasive gliomas frequently recur after treatment, resulting in death in nearly all cases. Many types of tumors including gliomas modify normal cells in their environment to bestow upon themselves malignant properties such as increased tumor growth, invasion and metastasis. Recently, we discovered that glioma cells have an insidious means of manipulating cells in their environment to gain cancerous advantages for themselves: exosomes (microvesicles). Exosomes are small vesicles produced in abundance by glioblastomas (GBMs), the highest grade of gliomas, and contain cellular proteins and genetic information designed to "take over" the surrounding recipient cells, making them to acquire pro-cancerous properties and consequently facilitate tumor progression. In this study, I will reversely employ GBM exosomes as a novel therapeutic gene vehicle to manipulate tumor environments in order to suppress tumor oncogenicity, and thereby turning the tumor cells into their own worst enemy. To develop this novel therapeutic paradigm, I will genetically engineer a subset of tumor cells to produce exosomes containing therapeutic "suicide genes" and subsequently investigate their effect in eradicating the tumor. Importantly, this devised "exosome therapy" also aims to destroy the tumor's surrounding cells which provide nutrients to propagate tumor development, as well as to kill peripheral cancer cells that often infiltrate into neighboring tissues. Altogether, this innovative project will open a new dimension to gene therapy against gliomas.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
214735
Name
Lai Charles P
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Therapeutic Manipulation of Glioblastoma Microenvironments using Tumor-derived Exosomes
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Brain Tumors; Cancer; Exosomes; Gene Therapy; Glioblastoma; Glioma; Lentivirus; Microvesicles; Molecular Biology; Prodrug
Abstract
Glioma is the most prominent type of CNS tumour and accounts for more than 65% of all primary brain tumors. Between Canada and the United States, more than 100,000 patients are diagnosed with a brain tumor annually, representing a major health burden on the individual as well as society. Furthermore, therapeutic strategies often pose a high risk of side effects to glioma patients due to its occurrence in the brain, and invasive gliomas frequently recur after treatment, resulting in death in nearly all cases. Many types of tumors including gliomas modify normal cells in their environment to bestow upon themselves malignant properties such as increased tumor growth, invasion and metastasis. Recently, we discovered that glioma cells have an insidious means of manipulating cells in their environment to gain cancerous advantages for themselves: exosomes (microvesicles). Exosomes are small vesicles produced in abundance by glioblastomas (GBMs), the highest grade of gliomas, and contain cellular proteins and genetic information designed to "take over" the surrounding recipient cells, making them to acquire pro-cancerous properties and consequently facilitate tumor progression. In this study, I will reversely employ GBM exosomes as a novel therapeutic gene vehicle to manipulate tumor environments in order to suppress tumor oncogenicity, and thereby turning the tumor cells into their own worst enemy. To develop this novel therapeutic paradigm, I will genetically engineer a subset of tumor cells to produce exosomes containing therapeutic "suicide genes" and subsequently investigate their effect in eradicating the tumor. Importantly, this devised "exosome therapy" also aims to destroy the tumor's surrounding cells which provide nutrients to propagate tumor development, as well as to kill peripheral cancer cells that often infiltrate into neighboring tissues. Altogether, this innovative project will open a new dimension to gene therapy against gliomas.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lai, Charles P
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2010-11) | Canada Spends